On October 6, 2025, Skye issued a press release "announcing the topline data from its 26-week Phase 2a CBeyondâ"¢ proof-of-concept study of nimacimab, its peripherally-restricted CB1 inhibitor antibody." The press release disclosed that the "the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo" and that "preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy." On this n ...

LOS ANGELES, Dec. 04, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Skye Bioscience, Inc., (“Skye” or the "Company") (NASDAQ: SKYE) investors off a class action on behalf of investors that bought securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”). Skye investors have until January 16, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal r ...

Core Points - Rosen Law Firm is reminding purchasers of Skye Bioscience, Inc. securities of the lead plaintiff deadline for a class action lawsuit, which is January 16, 2026 [1] - Investors who purchased Skye securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3] Case Details - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding Skye's business and prospects, particularly concerning the effectiveness of nimacimab [5] - Specific claims include that nimacimab was less effective than represented, leading to overstated clinical, regulatory, and commercial prospects [5] - The lawsuit asserts that when the true details became known, investors suffered damages [5] Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy of its lead product candidate, nimacimab, during the class period from November 4, 2024, to October 3, 2025 [1] Company Overview - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on developing treatments for obesity and metabolic diseases [1] Legal Proceedings - The lawsuit claims that Skye failed to disclose that the efficacy of nimacimab was lower than represented, leading to an overstatement of the drug's clinical and commercial potential [1] - Investors who purchased Skye securities during the class period have until January 16, 2026, to seek appointment as lead plaintiff [1] Stock Performance - Following the announcement of topline data from a Phase 2a study on October 6, 2025, which revealed that the primary endpoint of an 8% weight loss difference compared to placebo was not met, Skye's stock price fell by $2.85 per share, or 60%, closing at $1.90 [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Skye Bioscience, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - The Class Period for the Skye Bioscience securities is from November 4, 2024, to October 3, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3]. - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its performance in this area [3]. Group 3: Case Allegations - The lawsuit alleges that Skye Bioscience made materially false and misleading statements regarding its business and the effectiveness of its product, nimacimab [4]. - Specific claims include that nimacimab was less effective than represented, and its clinical and commercial prospects were overstated [4]. - The lawsuit claims that investors suffered damages when the true details about the product were revealed [4].

Summary of Skye Bioscience FY Conference Call Company Overview - **Company**: Skye Bioscience (NasdaqGM:SKYE) - **Focus**: Metabolic therapeutics, specifically developing a peripherally restricted CB1 antibody named Nemesumab - **Current Development Stage**: Phase 2 development with initial data reported from a 26-week trial Key Points and Arguments Clinical Data and Efficacy - The initial 26-week data from the phase 2 trial indicated that a 200-milligram dose of Nemesumab showed limited efficacy, establishing a floor for weight loss response [3][4] - A combination therapy with Semaglutide resulted in a 30% increase in weight loss compared to Semaglutide alone, with patients losing approximately 13% of their body weight over 26 weeks [3][11] - The company aims to achieve a weight loss trajectory of around 20% at the 52-week mark, positioning Nemesumab competitively against other therapies like CagriSema and tirzepatide [4][26] Mechanism of Action - The large molecule approach of Nemesumab is designed to avoid crossing the blood-brain barrier, reducing neuropsychiatric side effects associated with small molecules [5][6] - The combination of GLP-1 mechanism (caloric restriction) and CB1 inhibition (fat storage modulation) is believed to create a synergistic effect, enhancing weight loss [11][12] Safety and Dosing Strategy - The safety profile of Nemesumab is considered favorable, allowing for higher dosing without significant adverse effects [6][10] - Future dosing strategies may involve increasing the dose significantly beyond the current 200-milligram level, with estimates suggesting a range of 600 to 1,000 milligrams may be optimal based on preclinical data [21][23] Future Development Plans - The company is prioritizing the combination therapy while keeping options open for monotherapy, especially if it can achieve a weight loss target of 5%-8% [25][30] - An extension study is set to report data in Q1, which will inform the design of a potential phase 2B trial [30] Additional Important Insights - The company is exploring formulation and delivery technologies to facilitate at-home administration of higher volume injections [24] - There is a nuanced approach to interpreting data from patients who may have treatment gaps, particularly in the monotherapy group [28][29] - The competitive landscape is acknowledged, with a focus on demonstrating superior efficacy and safety profiles compared to existing therapies [26][30]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Faruqi & Far ...

Core Viewpoint - Rosen Law Firm is encouraging investors of Skye Bioscience, Inc. to secure legal counsel before the January 16, 2026 deadline for a class action lawsuit related to securities purchased between November 4, 2024, and October 3, 2025 [2][3]. Group 1: Class Action Details - Investors who purchased Skye securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [4]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Skye's business and the effectiveness of its product, nimacimab, which led to investor damages when the truth was revealed [6]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [5]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5].

What can I do now? You may be eligible to participate in the class action against Skye Biosciences, Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers with the court by January 16, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information ...

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Skye Bioscience, Inc. (NASDAQ: SKYE) securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”). The lawsuit seeks to recover losses for investors under the federal securities laws. What if I purchased Skye Bioscience securities?If you purchased Skye Bioscience securities during the Class Period and suff ...